TLR7 and cancer: A number of TLR agonists are currently in trial as adjuvants for cancer vaccines, one of the most commonly used TLR agonist is polyinosinic–polycytidylic acid with polylysine and carboxymethylcellulose (Poly-ICLC) a TLR3 agonist (93), others include monophosphoryl lipid A (MPLA) a TLR4 agonist (94, 95), imiquimod a TLR7 agonist (96, 97), resiquimod a TLR7 and TLR8 agonist (98, 99), CpG oligodeoxynucleotide (CpG ODN) a TLR9 agonist (90, 100, 101).